Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682302 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL
A Phase 3 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
NCT03682302 is a Phase 3 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT03682302, a Phase 3 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries. Secondary Objective: To evaluate the safety of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.
Interventions
- DRUG Exparel
- DRUG 0.5% Bupivacaine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03682302
The ClinicalTrials.gov registry entry for NCT03682302 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT03682302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03682302 about?
NCT03682302 is a clinical study titled "Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL". Primary Objective: To evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries. Secondary Objective: To evaluate the safety of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeri...
What is the current status of trial NCT03682302?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2019-04-02. Estimated completion is 2019-09-24.
What interventions are being tested in trial NCT03682302?
The interventions under investigation include: Exparel (DRUG), 0.5% Bupivacaine HCl (DRUG).
Who is sponsoring clinical trial NCT03682302?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.